LAG3 and head and neck squamous cell carcinoma: A phase II neoadjuvant study to determine the safety and tolerability of nivolumab alone or in combination with anti-LAG-3 (relatlimab) or anti-CTLA-4 (ipilimumab) in resectable HNSCC is under clinical trial (134).